Ten Years in the Market. This Is the Company We Built While No One Was Watching.

Every company has an origin story, and many of them are messy.

P.S.S. Urology's early years carried the characteristics common to many founder-led startups in the medical device space: a product with genuine market potential, real customers, and real revenue alongside the organizational fragility, unfocused strategy, and structural complications that founder-stage companies frequently accumulate before anyone pauses long enough to address them.

The product worked. The market was real. Surgeons were using P.S.S. electrodes in urology suites across the country, and they were reordering them. Repeat purchases, clinical acceptance, and recurring revenue were always present, even when almost everything around it needed work.

But the foundation had problems. The product portfolio had spread itself thin across categories that diluted focus without adding proportionate value. The organizational infrastructure was informal in ways that work at small scale and fail under growth. The capital structure carried obligations that constrained decision-making. And the systems, processes, and accountability frameworks that a professionally run company requires, the things that allow an organization to manage complexity, sustain quality, and scale with confidence, were largely absent.

The combination of strong core, difficult structure is exactly the kind of situation that either breaks a company or builds something durable, depending entirely on what leadership chooses to do next.

‍

What happened next did not generate a press release.

There was no rebranding campaign, no fundraising announcement, no public declaration that P.S.S. Urology was undergoing a transformation. The company continued to serve its customers, pay its team, fulfill its orders, and grow its revenue. From the outside, the business looked like a focused specialty distributor executing consistently in a defined market. That description was accurate. It was also incomplete.

Inside the building, a parallel effort was underway.

The team was assessed honestly. Individuals who had served the company well in its early chapter, but who were not positioned to contribute to the next one were transitioned with respect. They were replaced with people whose capabilities matched what the business actually needed to become, not what it had been. That process is never comfortable. It requires a leader to hold two things simultaneously: genuine appreciation for what people contributed in the past, and unflinching clarity about what the organization requires going forward.

The product portfolio was rationalized. Laser fibers, bladdervacs, ancillary equipment lines, and unpopular consumables were exited cleanly. The decision was deliberate: concentrate entirely on disposable electrosurgical electrodes, the product with the clearest clinical value, the strongest recurring economics, and the most defensible position in the urology OR. Electrode revenue grew from its early base at a 28% compound annual rateover the five years that followed. The business became more focused, more predictable, and more valuable as a result.

Operational and financial systems were built from scratch. Professional financial infrastructure, supply chain management tools, CRM andsales operations capability, quality and compliance frameworks were built.  None of these existed at the level required to support a scaling business. They were built, methodically and without fanfare, as the prerequisites for everything the growth plan would eventuallyrequire.

Debt was retired. Not restructured. Not deferred. Paidoff.  Seven separate obligations, resolved one by one from operating cash flow, without adding a single dollar ofnew borrowing. This discipline was maintained over five years, through a period that included active litigation, a compounding inherited liability the CEO was legally constrained from touching, and the ordinary pressures of running agrowing business with limited resources.

A formal operating framework was adopted to replace thefounder-dependent management model with one built on process, accountability,and disciplined execution rhythms. The organization that emerged from thattransition is more resilient, more self-directing, and more capable ofsustaining growth than the one that preceded it.

None of this was announced. None of it was visible to the market. It was simply the work that needed to be done.  And it got done.

‍

‍

By the time the rebuild was complete, the evidence was in the operating results, and the results are unambiguous.

Revenue grew from $2.47 million to $6.95 million over five years. That is a 181% increase, compounding at 23% annually, sustained across every year of the period, through a global pandemic, through active litigation, and through a capital structure that would have constrained a less disciplined organization. The growth was not driven by a single event or a single customer. It was built year by year, territory by territory, account by account.

The business achieved profitability. Operating income swung by more than $2.5 million over five years from a loss to a sustained and growing profit. Cash reserves were built from about $10,000 at the start of this period to more than $1 million, without borrowing to do it.

A national network of more than 70 independent sales professionals now covers hospitals and ambulatory surgical centers across the United States. The company generates approximately $1 million in annual revenue per employee, a benchmark that rivals best-in-class technology and SaaS companies, and that is exceptional for a physical-product medical device business with national distribution.

The customer base of OR directors, supply chain managers, and the surgical teams that use P.S.S. electrodes in procedure after procedure demonstrates the kind of loyalty that only comes from consistent product performance, reliable availability, and service that earns trust over time. These customers are not new relationships. Many of them have been buying from P.S.S. for years. That continuity is not an accident. It is the result of a decade of presence, and of a second act that quietly made the company worthy of the loyalty it was receiving.

‍

‍

P.S.S. Urology is not a startup with potential.

It is a mature, profitable, operationally sound medical device company with ten years in the urology market, a national independent sales presence, a proven recurring-revenue model, and a leadership team that has already demonstrated the ability to execute through legal, financial, operational, and organizational adversity without losing momentum.

The foundation is not something being built. It has been built. What comes next is growth on top of something real.

The growth plan ahead is ambitious. Expanding geographic coverage, deepening account penetration, and developing the next generation of proprietary clinical electrosurgical technology are all part of what this company is building toward. That ambition is appropriate and it is credible precisely because of what has already been demonstrated. The capabilities the next chapter requires are not aspirational. They are the capabilities this leadership team has already proven it possesses.

‍

The honest answer is simple: because it is time.

For years, the work of rebuilding was more important than the work of communicating. The foundation needed to be right before the story was worth telling. It is right now. And as P.S.S. Urology steps into a broaderset of market conversations with partners, with investors, and with clinical stakeholders evaluating what kind of company they want to work with those conversations deserve to be anchored in the full picture.

Ten years in the market. A company tested early and quietly rebuilt from the inside. A track record that speaks to who this leadership team is and how it operates. A growth plan built on a foundation that has already been stress-tested by reality.

That is the introduction P.S.S. Urology is choosing tomake.

P.S.S. Urology develops and distributes disposable electrosurgical consumables for the urology market, with a national independent representative network serving hospitals and ambulatory surgical centers across the United States. To follow the company's ongoing story, subscribe to this blog or reach out directly.

© 2026 P.S.S. Urology. All rights reserved.

‍